GlobeNewswire·Jul 27, 2026, 4:05 PM ET

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Scribe Therapeutics Inc. (NASDAQ: SCTX) closed an upsized initial public offering of 9,867,000 common stock shares at $15.00 per share, including the full exercise of the underwriters' option for 1,287,000 additional shares.
The company's common stock commenced trading on the Nasdaq Global Market on July 24, 2026.
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, & Wells Fargo Securities served as joint book-running managers for the offering.
Aggregate gross proceeds from the IPO, including the full underwriters' option & a concurrent private placement, totaled approximately $155.51 million before deducting underwriting discounts & commissions.
A registration statement became effective with the SEC on July 23, 2026, & the offering was conducted solely via a prospectus filed with the SEC.
On July 27, 2026, Scribe Therapeutics closed a concurrent private placement of 500,000 shares to Sanofi at the IPO price of $15.00 per share, which was unregistered under the Securities Act of 1933.
Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR technologies to treat cardiometabolic diseases, with lead candidate STX-1150 targeting the PCSK9 gene to reduce LDL-C levels.
The company was co-founded by Nobel Prize winner Jennifer Doudna & maintains strategic collaborations with Sanofi & Eli Lilly.